Managing Menopause



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2000 Mar 1;61(5):1391-1400.

  Related Editorial

Many women will spend one third of their lifetime after menopause. A growing number of options are available for the treatment of menopausal symptoms like vasomotor instability and vaginal atrophy, as well as the long-term health risks such as cardiovascular disease and osteoporosis that are associated with menopause. Currently, hormone replacement therapy (estrogen with or without progestin) is the primary treatment for the symptoms and long-term risks associated with menopause. However, recent evidence calls into question the protective effect of estrogen on cardiovascular disease risk. The association of risk for breast cancer with estrogen replacement therapy also has not been fully clarified. In addition, many women cannot or choose not to take hormones. For treatment of osteoporosis and heart disease, pharmacologic choices include antiresorptive agents such as bisphosphonates and calcitonin, and estrogens or selective estrogen receptor modulators such as raloxifene. In addition, complementary options that include vitamins, herbal treatments, exercise and other lifestyle adaptations are gaining increased interest. The growing number of choices and questions in this area emphasizes the need to individualize a treatment plan for each woman to meet her specific needs.

For nearly 70 percent of women, the transition into menopause is smooth1; however, many women seek advice for management of associated symptoms such as hot flushes or vaginal dryness, or for assistance in the prevention of associated long-term health problems such as osteoporosis and coronary artery disease.

Women and physicians have questions and concerns about the use of hormone replacement therapy (HRT) during and after menopause. In addition, many alternative and nonhormonal treatments lack rigorous scientific study but are popular with patients. Family physicians need to know the available treatment options in order to address patients' questions and concerns.

Pharmacologic Therapy for Symptoms of Menopause

VASOMOTOR INSTABILITY

A hot flush is a flushed or blushed feeling of the face, neck and upper chest. Skin temperature can rise several degrees. The severity of hot flushes increases with fatigue and stress. The most severe hot flushes usually occur at night and may adversely affect sleep. About 75 percent of American women experience hot flushes during menopause, although not all are subjectively troublesome. Menopausal women living in Asian countries experience a much lower incidence of hot flushes and sleep disturbance, which may be related to dietary factors such as phytoestrogens that are contained in soy products.2 Hot flushes may persist for several years around the time of menopause.

Estrogen therapy can reduce hot flushes. Progesterone therapy alone may help women who choose not to take estrogen. Clonidine (Catapres), a centrally acting alpha-adrenergic agonist, has also been used with mixed success.3

PSYCHOLOGIC SYMPTOMS

Mood swings, depression and concentration difficulties are psychologic symptoms that are associated with menopause. Estrogen therapy improves mood and dysphoria, possibly by affecting the metabolism of serotonin in the central nervous system.4 However, depression has not been shown to be caused by menopause alone but is usually the result of additional factors that include previous history of depression, psychologic factors and life stressors that may accumulate around the time of menopause.3 While estrogen improves mood or dysphoria associated with menopause, HRT is not effective in the treatment of primary depression.

UROGENITAL SYMPTOMS

The urogenital tissues are estrogen sensitive. Declining estrogen levels lead to atrophy of the urogenital tissues and vaginal thinning and shortening, resulting in dyspareunia and urethral irritation. In addition, urinary tract infections and urinary incontinence may develop because of tissue thinning, laxity, decreased urethral apposition and alteration of the vaginal flora.

A meta-analysis of estrogen treatment (oral or intravaginal) for urinary incontinence revealed a significant improvement in subjective symptoms, but no improvement in objective measures such as urodynamic testing.5 Intravaginal estrogen administration has been shown to decrease the number of recurrent urinary tract infections.6 Doses of estriol 0.5 mg administered intravaginally did not cause a significant rise in plasma estrogen levels within 24 hours. The risk of endometrial cancer is low with this regimen.6

Pharmacologic Management of Long-Term Risks

CORONARY ARTERY DISEASE

Estrogen's physiologic effects, such as arterial vasodilatation, decreased fibrinogen levels, increased high-density lipoprotein (HDL) cholesterol levels and decreased low-density lipoprotein (LDL) cholesterol levels, are likely to reduce cardiovascular risk. Unopposed estrogen offers the most beneficial effect on HDL cholesterol levels; however, the addition of progestin agents does not negate improvement.7 Oral estrogen can increase the serum HDL level by 20 to 30 percent and reduce the serum LDL level by 10 to 15 percent. The effect is comparable to or better than that of a statin drug.8

Many observational studies have shown that estrogen is associated with a 40 to 50 percent reduction in the risk of heart disease.911 Meta-analyses of these nonrandomized trials911 demonstrated a pooled reduction in relative risk of heart disease of one third in women who had ever used estrogen.12,13

Conversely, the results of the Heart and Estrogen/Progestin Replacement Study (HERS),14 a recent randomized, controlled trial, found no benefit of HRT for secondary prevention of cardiovascular events in 2,763 postmenopausal women followed over four years.14 Although the conflicting results illustrate the shortcomings of nonrandomized trials and raise caution, it should be noted that the HERS participants had established coronary heart disease, and 25 percent of the women in the active treatment arm dropped out of this study. Perhaps HRT provides minimal to no benefit in women with established coronary heart disease but may provide primary prevention in otherwise healthy women.

The protective effect of estrogen against stroke is unclear. The National Health and Nutrition Examination Survey15 found an adjusted relative risk of 0.37 (95 percent confidence interval [CI]; range: 0.14 to 0.92) for fatal stroke in women who had ever used estrogen. In the Leisure World Study,9 the risk of death from stroke for women who were taking estrogen was reduced by 20 to 40 percent. Other studies have illustrated no protection against stroke.10,16

Critics of HRT studies state that women who take estrogen may be better informed and healthier than women who choose not to take estrogen. Most studies do not have the rigorous design of a randomized, controlled trial, which is necessary to ascertain whether the estrogen or the associated healthier attitudes and practices of the participants are the major causes of reduced disease. Until such information is available, HRT is considered important in the primary prevention of cardiovascular disease; however, questions remain about its role in secondary cardiovascular risk reduction.

OSTEOPOROSIS

In the United States, 4 to 6 million women have osteoporosis. One consequence of this situation is that more than 250,000 hip fractures occur annually, with a health care cost of approximately $14 billion per year. A hip fracture carries a 10 to 20 percent risk of death within a year and a 25 percent chance of institutionalization.17 Estrogen deficiency is the primary cause of osteoporosis, although many other secondary causes for osteoporosis exist (e.g., poor diet, glucocorticoid excess). Thus, women at risk for osteoporosis should be considered candidates for HRT.

The daily dosage required to prevent bone loss is 0.625 mg of conjugated estrogen or the equivalent (Table 1), but even 0.3 mg may suffice if taken with adequate calcium supplements. Resumption of bone loss following discontinuation of HRT has been reported.18 The maximal protective effect of estrogen on bone mineral density (BMD) occurs if HRT is initiated within three years of menopause. However, effectiveness has been documented with initiation of therapy in the later years of menopause.9

TABLE 1.

Minimum Effective Dosages of Estrogens for Prevention of Osteoporosis

Formulation* Minimum effective dosage Cost

Conjugated estrogen

0.625 mg

$15

Premarin (0.3, 0.625, 0.9, 1.25, 2.5)

Micronized estradiol

1.0 mg

14

Estrace (0.5, 1.0, 2.0)

Esterified estrogen

0.625 mg

Estratab (0.3, 0.625, 2.5)

14

Menest (0.3, 0.625, 1.25, 2.5)

6

Estropipate

1.25 mg

Ogen (0.625, 1.25, 2.5)

27

Ortho-Est (0.625, 1.25)

22

Transdermal estradiol

0.05 mg

Alora (0.05, 0.075, 0.1)

19

Climara (0.05, 0.1)

23

Estraderm (0.05, 0.1)

22

Fempatch (0.025)

25

Vivelle (0.0375, 0.05, 0.75, 0.1)

23

Combination preparations

Combipatch

0.05 mg estradiol/0.14 mg norethindrone

30

Estratest

1.25 mg esterified estrogen/2.5 mg methyltestosterone

31

Estratest HS

0.625 mg esterified estrogen/1.25 mg methyltestosterone

25

Premphase‡

0.625 mg conjugated estrogen (14 tablets) and 0.625 mg conjugated estrogen/5 mg medroxyprogesterone acetate (14 tablets in sequence)

20

Prempro

0.625 mg conjugated estrogen/2.5 mg or 5.0 mg medroxyprogesterone acetate

22 each

Vaginal preparations

Micronized estradiol cream (Estrace)

0.01 % or 0.1 mg per g (42.5 g/tube)

36§

Estropipate cream (Ogen)

1.5 mg per g (42.5 g/tube)

48§

Conjugated estrogen cream (Premarin)

0.625 mg per g (42.5 g/tube)

42

Dienestrol cream (Ortho)

0.01 % or 0.1 mg per g (78 g/tube)

30§

Estradiol vaginal ring (Estring)

7.5 μg per 24 hours every 90 days

69


*—Not all dosages are available in all brands; available dosages are listed.

†—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar) for one month of therapy at the minimum effective dosage in Red book. Montvale, N.J.: Medical Economics Data, 1999. Cost to the patient will be greater, depending on prescription filling fee.

‡—Two separate tablets in monthly pack. Estrogen-only tablet for first 14 days of the month. Combination tablet for the next 14 days.

§—Price per tube.

TABLE 1.   Minimum Effective Dosages of Estrogens for Prevention of Osteoporosis

View Table

TABLE 1.

Minimum Effective Dosages of Estrogens for Prevention of Osteoporosis

Formulation* Minimum effective dosage Cost

Conjugated estrogen

0.625 mg

$15

Premarin (0.3, 0.625, 0.9, 1.25, 2.5)

Micronized estradiol

1.0 mg

14

Estrace (0.5, 1.0, 2.0)

Esterified estrogen

0.625 mg

Estratab (0.3, 0.625, 2.5)

14

Menest (0.3, 0.625, 1.25, 2.5)

6

Estropipate

1.25 mg

Ogen (0.625, 1.25, 2.5)

27

Ortho-Est (0.625, 1.25)

22

Transdermal estradiol

0.05 mg

Alora (0.05, 0.075, 0.1)

19

Climara (0.05, 0.1)

23

Estraderm (0.05, 0.1)

22

Fempatch (0.025)

25

Vivelle (0.0375, 0.05, 0.75, 0.1)

23

Combination preparations

Combipatch

0.05 mg estradiol/0.14 mg norethindrone

30

Estratest

1.25 mg esterified estrogen/2.5 mg methyltestosterone

31

Estratest HS

0.625 mg esterified estrogen/1.25 mg methyltestosterone

25

Premphase‡

0.625 mg conjugated estrogen (14 tablets) and 0.625 mg conjugated estrogen/5 mg medroxyprogesterone acetate (14 tablets in sequence)

20

Prempro

0.625 mg conjugated estrogen/2.5 mg or 5.0 mg medroxyprogesterone acetate

22 each

Vaginal preparations

Micronized estradiol cream (Estrace)

0.01 % or 0.1 mg per g (42.5 g/tube)

36§

Estropipate cream (Ogen)

1.5 mg per g (42.5 g/tube)

48§

Conjugated estrogen cream (Premarin)

0.625 mg per g (42.5 g/tube)

42

Dienestrol cream (Ortho)

0.01 % or 0.1 mg per g (78 g/tube)

30§

Estradiol vaginal ring (Estring)

7.5 μg per 24 hours every 90 days

69


*—Not all dosages are available in all brands; available dosages are listed.

†—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar) for one month of therapy at the minimum effective dosage in Red book. Montvale, N.J.: Medical Economics Data, 1999. Cost to the patient will be greater, depending on prescription filling fee.

‡—Two separate tablets in monthly pack. Estrogen-only tablet for first 14 days of the month. Combination tablet for the next 14 days.

§—Price per tube.

Study results demonstrate the efficacy of estrogen in increasing BMD and decreasing the number of fractures of the forearm, vertebrae and hip.19,20 Thus, HRT is not only preventive but can also be used to treat established osteoporosis. Spinal BMD has been shown to increase by 10.6 percent12 and hip BMD by 5.5 percent over a two-year period with HRT. The relative risk of hip fracture was 0.65 (95 percent CI; range: 0.44 to 0.98) in women who had taken estrogen at any time and 0.32 (95 percent CI; range: 0.12 to 0.98) in those taking estrogen within the past two years.21 In one large study, the incidence of all osteoporotic fractures was estimated to be reduced by 30 to 50 percent with long-term HRT (three to 10 years' duration).22

Alternatives to HRT include bisphosphonates, which inhibit osteoclast activity and localize and bind to resorption sites on the bone. The current recommended therapeutic course is three years, to avoid the potential risk of osteomalacia. Long-term data are forthcoming. Alendronate (Fosamax) is labeled by the U.S. Food and Drug Administration for treatment of osteoporosis. Several large, randomized, controlled trials have demonstrated its efficacy in increasing BMD and reducing fractures by 40 percent.23,24 To prevent esophagitis, alendronate should be taken in an upright position with a full glass of water 30 minutes before eating; the upright position should be maintained for the 30 minutes. This agent may cause musculoskeletal pain and gastrointestinal upset. Contraindications include symptomatic upper gastrointestinal disease (esophageal stricture, achalasia, gastroesophageal reflux) and renal insufficiency.

Etidronate (Didronel) is another bisphosphonate. It is FDA-labeled for treatment of Paget's disease, but has had an unlabeled use as a treatment for osteoporosis in patients who cannot tolerate alendronate. In one study,25 it was documented in a sample of 66 women with postmenopausal osteoporosis that etidronate increased vertebral BMD 5.3 percent (95 percent CI; range: 2.0 to 8.6) and reduced fracture rate (six versus 54 fractures per 100 patient years) over three years. The patients in the intervention arm received etidronate in a dosage of 400 mg per day for two weeks every 15 weeks for three years. This agent has proved effective in increasing vertebral BMD and reducing fracture rates. It is more cost effective than alendronate.22

Intranasal calcitonin (Mialcalcin) is a polypeptide hormone that also inhibits osteoclastic activity. An injectable form has been available for about 15 years; however, a convenient intranasal form is now available for treatment of established osteoporosis. In a randomized, placebo-controlled trial, 76 percent of post-menopausal women receiving a dosage of 200 IU per day intranasally demonstrated a positive response, with a 2.0 to 3.6 percent increase in BMD, while participants receiving placebo lost bone mass.26,27 No data are available on change in fracture rate.

A new selective estrogen receptor modulator, raloxifene (Evista), has been FDA-labeled for prophylactic treatment of osteoporosis. For women whose main interest is prevention of osteoporosis, this agent offers an alternative to traditional HRT. The modulator does not stimulate endometrial or breast tissue but does increase BMD (although only approximately one half as effectively as estrogen) and reduce total and LDL cholesterol levels with no change in triglycerides or HDL cholesterol levels.28 Longitudinal studies are needed to determine the net effect on cardiovascular disease and breast cancer. Other selective estrogen receptor modulators pending FDA labeling include droloxifene and idoxifene.

COGNITIVE FUNCTION

The evidence concerning prevention of dementia with HRT is conflicting but promising. Observational studies have demonstrated a protective effect and no effect on the risk of Alzheimer's dementia. A meta-analysis of the observational studies of estrogen use and development of dementia have shown an odds ratio of 0.71 (95 percent CI; range: 0.52 to 0.98).29 Prospective randomized trials are needed. Proposed mechanisms of action include increased blood flow to the brain and enhanced neuronal dendritic growth to support neurotransmitter production.

LONGEVITY

The mortality rate among women who take estrogen has been shown to be lower than the rate in women who do not. The Nurses Health Study16 (data from 1976 to 1994) revealed decreased mortality in women who took estrogen; however, the benefit decreased with longer duration of use and was lower in women already considered at low risk for coronary artery disease. Other studies have shown lower all-cause mortality rates among women taking HRT.30

The issue of HRT among special populations of women (i.e., survivors of breast cancer) has not been adequately addressed. Trials are currently under way to address this issue.

HRT Administration and Regimens

The most common HRT regimen consists of estrogen with or without progestin. Transdermal estrogen preparations avoid the first-pass liver effect. This may be efficacious in the treatment of vasomotor symptoms but may also reduce the positive effect on cholesterol levels. Many women have a problem with skin sensitivity to the patches. Vaginal preparations are widely used, especially for treatment of atrophic vaginitis. Injectable and slow-release implant formulations of estrogen are available but are not preferred by many patients. Despite the availability of a variety of administration routes, the concern about coronary artery disease makes the oral route of administration preferable because of the hepatic effect on HDL cholesterol levels.

Estrogen-only regimens are appropriate in women who have undergone hysterectomy. The paucity of data showing that progestins protect against an increased risk of breast cancer and the concern regarding the adverse effect of progestins on lipoproteins make the estrogen-only regimen preferable to combined therapy in women without a uterus.

Progestin should be added to the estrogen-only regimen for at least 12 days per month in women with an intact uterus to avoid the five-to eightfold risk of endometrial adenocarcinoma resulting from unopposed estrogen use. If progestins are not tolerated, women who have not had a hysterectomy may be followed closely on an estrogen-only regimen with an annual endometrial biopsy, uterine ultrasonography or progesterone challenges,31 to screen for endometrial hyperplasia.

Postmenopausal women generally dislike cyclic regimens because they mean resumption of menses. Continuous regimens are the most widely accepted. Oral pill (singly or in combination) and combination skin patch (Combipatch) formulations are available. Vaginal bleeding may occur during the first six months of therapy; however, amenorrhea is usually achieved after the first year. Some authors recommend that patients undergo a pretreatment endometrial biopsy to exclude hyperplasia before initiating hormone therapy; others believe this is unnecessary in asymptomatic women and recommend biopsy only if bleeding persists past six months of therapy.32

THE ROLE OF ANDROGENS/TESTOSTERONE

Interest is growing in the use of androgens to enhance well-being during post-menopausal therapy.

Androgenic hormones are produced in the ovaries and the adrenal glands and act on musculoskeletal, nervous, hepatic and vascular tissues. Androgens are known to increase libido and protect bone mass.33,34 However, lipid profiles change when androgens are added to HRT. The HDL fraction decreases with androgen therapy; however, triglyceride concentrations decrease significantly in patients given estrogen-androgen combination therapy. HDL cholesterol and triglyceride levels may be important factors in determining cardiac risk.34

Adverse effects such as virilization are few and can be minimized with reduction of the dosage. Considering the subsequent lipid effect (although without information from long-term studies), it is probably prudent to avoid androgen therapy in women with known low HDL cholesterol levels and established cardiovascular disease.34

ADVERSE EFFECTS

Forty percent of women discontinue HRT within eight months of initial therapy or never fill the prescription.35  Adverse effects attributed to HRT include breast tenderness, breakthrough bleeding, cancer (breast or endometrial) and thromboembolic disorders. In addition, there are relative and absolute contraindications to the use of HRT (Table 2). 35,36 The Nurses' Health Study38 reported that risk of breast cancer was highest among women who received HRT for five years or longer (relative risk: 1.45; 95 percent CI; range: 1.01 to 2.09). No elevated risk associated with past use was reported. A collaborative analysis of 51 studies showed an increased risk with duration of therapy (relative risk: 1.35; P = 0.0001), although the excess numbers of breast cancers were small.39 A definitive answer has not emerged from the large number of studies, suggesting that the risk of breast cancer is relatively low. Randomized, controlled trials are needed, and the Women's Health Initiative may provide more answers.

TABLE 2.

Relative and Absolute Contraindications for Hormone Replacement Therapy

Absolute contraindications

Estrogen-responsive breast cancer

Endometrial cancer

Undiagnosed abnormal vaginal bleeding

Active thromboembolic disease

History of malignant melanoma

Relative contraindications

Chronic liver disease

Severe hypertriglyceridemia

Endometriosis

Previous thromboembolic disease

Gallbladder disease


Information from Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37, and Reuben DB, ed. Geriatric review syllabus A core curriculum in geriatric medicine. 3rd ed. New York: AGS, 1996.

TABLE 2.   Relative and Absolute Contraindications for Hormone Replacement Therapy

View Table

TABLE 2.

Relative and Absolute Contraindications for Hormone Replacement Therapy

Absolute contraindications

Estrogen-responsive breast cancer

Endometrial cancer

Undiagnosed abnormal vaginal bleeding

Active thromboembolic disease

History of malignant melanoma

Relative contraindications

Chronic liver disease

Severe hypertriglyceridemia

Endometriosis

Previous thromboembolic disease

Gallbladder disease


Information from Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37, and Reuben DB, ed. Geriatric review syllabus A core curriculum in geriatric medicine. 3rd ed. New York: AGS, 1996.

Complementary Therapies

Many herbal substances and similar products have been suggested as therapeutic agents in managing menopause, but most lack scientific proof of efficacy.

Natural progesterone, present in yam root, is touted as a remedy for premenstrual and menopausal symptoms. The natural ingredient, disogenin, is not well absorbed orally, and special compounding into a topical cream is necessary. The standard dosage is 40 to 1,000 mg per day of the 1.5 or 3.0 percent topical formulation, applied twice daily to areas with soft tissue (e.g., abdomen, inner thighs). It is also available in an oral micronized form, Prometrium, and considered to have no adverse side effects at standard doses.40,41

Soy products contain compounds known as isoflavones (natural phytoestrogens), which are 500 to 1,000 times weaker than endogenous estrogen. Soy protein appears to be effective in reducing hot flushes, bone loss and total and LDL cholesterol levels. It may also inhibit the growth of different cancer cell lines in vitro and in vivo.42 Food sources include soy nuts, soy milk and tofu.

Several other natural substances have been used to treat menopausal symptoms. These substances include vitamin E, which is thought to stabilize estrogen levels; black cohosh (Cimicifuga racemosa), marketed in the United States as Remifemin (standard dosage: 40 mg per day), thought to suppress luteinizing hormone; and Chasteberry (Vitex agnuscastus), which may decrease prolactin. None of these products has been examined or has proved effective in well-designed clinical trials. Other substances, such as dong quai (Angelica sinensis) and licorice root (Glycyrrhiza glabra) are not considered helpful. No herbal derivative has been shown to be effective in the prevention or treatment of osteoporosis.43

Adequate dietary calcium intake is essential, and supplementation is helpful if dietary sources are inadequate. Total calcium intake should approximate 1,500 mg per day, which usually requires supplementation.

Mounting evidence suggests that vitamin D deficiency may be more prevalent than previously believed. Vitamin D supplementation (400 to 800 IU per day), in addition to calcium supplementation, is recommended for women who cannot spend 30 minutes per day in the sun.44

Counseling Patients

Several lifestyle approaches may be recommended for the management of menopausal symptoms in general (Table 3). Most are common-sense recommendations that apply to a healthy lifestyle.

TABLE 3.

Lifestyle Approaches for Wellness in Menopause

Approaches Advantages

Diet

High fiber

Decreases CAD risk

Low fat

Improves cholesterol profile

Rich in antioxidants

May decrease hot flushes and other menopausal symptoms

Increased intake of soy products

Exercise

Cardiovascular

Decreases CAD risk

Weight-bearing

Improves cholesterol profile

Strengthening

Decreases osteoporosis risk, decreases risk of falls, may decrease hot flushes, may improve depressive symptoms, aids sleep, helps prevent weight gain

Smoking cessation

Decreases CAD risk, decreases osteoporosis risk, may decrease hot flushes

Decrease alcohol intake

May decrease hot flushes, decreases osteoporosis risk

Maintain regular sexual activity

May decrease vaginal dryness, may improve depressive symptoms

Daily sunlight

May improve depressive symptoms, decreases osteoporosis risk

Relaxation and stress reduction

Decreases CAD risk, may improve depressive symptoms


CAD = coronary artery disease.

TABLE 3.   Lifestyle Approaches for Wellness in Menopause

View Table

TABLE 3.

Lifestyle Approaches for Wellness in Menopause

Approaches Advantages

Diet

High fiber

Decreases CAD risk

Low fat

Improves cholesterol profile

Rich in antioxidants

May decrease hot flushes and other menopausal symptoms

Increased intake of soy products

Exercise

Cardiovascular

Decreases CAD risk

Weight-bearing

Improves cholesterol profile

Strengthening

Decreases osteoporosis risk, decreases risk of falls, may decrease hot flushes, may improve depressive symptoms, aids sleep, helps prevent weight gain

Smoking cessation

Decreases CAD risk, decreases osteoporosis risk, may decrease hot flushes

Decrease alcohol intake

May decrease hot flushes, decreases osteoporosis risk

Maintain regular sexual activity

May decrease vaginal dryness, may improve depressive symptoms

Daily sunlight

May improve depressive symptoms, decreases osteoporosis risk

Relaxation and stress reduction

Decreases CAD risk, may improve depressive symptoms


CAD = coronary artery disease.

A woman's current health status, personal health risks and beliefs should guide the management of symptoms and health risks related to menopause. The goals of therapy and the risks and benefits of the various treatment options should be presented and discussed. On average, the incidence of heart disease far outpaces the risk of breast cancer (a 1 in 2 versus 1 in 8 chance, respectively); but clearly, the fear of breast cancer emerges as a more powerful influence in the decision-making process for many women. Although breast cancer may claim 43,000 lives per year, coronary artery disease claims 223,000 lives and hip fractures claim 65,000 lives annually.45

In a model to assess the impact of HRT on life expectancy based on the risks of coronary artery disease, hip fracture and breast cancer, the benefit of HRT outweighed the risk of breast cancer in nearly all women. However, long-term HRT was not recommended for women at low risk for coronary artery disease or at high risk for breast cancer.45 Despite the HERS results showing no benefit from HRT in secondary prevention of cardiovascular disease, the recommendation of HRT for primary prevention of coronary artery disease is probably still prudent.46

For women interested in taking herbal remedies for the management of menopausal symptoms, it is important to provide basic medicinal information about these agents. Much of the data are published in German and gathered from studies performed in the 1960s. Patients should become familiar with each herb chosen, including its actions and side effects. Some herbs can cause harmful reactions such as severe diarrhea, allergic reactions, hallucinations and liver toxicity.

Many options are available for managing the symptoms and long-term risks associated with menopause. Ultimately, the available treatment choices may allow individualization of a therapeutic plan to manage menopause.

The Authors

TONI M. CUTSON, M.D., M.H.S., is assistant medical director in the Extended Care and Rehabilitation Center at the Geriatric Research, Education and Clinical Center of the Durham Veterans Affairs Medical Center, Durham, N.C. She also has an appointment in the departments of Community and Family Medicine, and Medicine at Duke University Medical Center, Durham. Dr. Cutson graduated from Virginia Commonwealth University Medical College, Richmond, and completed a family medicine residency at Chesterfield Family Practice, also in Richmond. She then completed a geriatric medicine fellowship and obtained a master's degree in health sciences from Duke University Medical Center.

EMILY MEULEMAN, M.S., R.N.C., is an ANCC-certified gerontologic nurse practitioner at the University of Michigan Chelsea Family Practice Center, Ann Arbor. She obtained an undergraduate degree in nursing at Nazareth College, Kalamazoo, Mich. She completed a master's degree in community health nursing and post-master's gerontologic nurse practitioner courses at the University of Michigan, Ann Arbor.

Address correspondence to Toni M. Cutson, M.D., M.H.S., GRECC #182, Durham Veteran's Affairs Medical Center, Durham, NC 27705. Reprints are not available from the authors.

REFERENCES

1. Porter M, Penney GC, Russell D, Russell E, Templeton A. A population based survey of women's experience of the menopause. Br J Obstet Gynaecol. 1996;103:1025–8.

2. Lock M. Contested meanings of the menopause. Lancet. 1991;337:1270–2.

3. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062–71.

4. Sherwin BB. Hormones, mood and cognitive functioning in postmenopausal women. Obstet Gynecol. 1996;87(suppl 2):20S–6S.

5. Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of estrogen supplementation in the treatment of urinary incontinence. The Continence Program for Women Research Group. Obstet Gynecol. 1996;88:745–9.

6. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329:753–6.

7. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199–208[Published erratum in JAMA 1995;274:1676].

8. Davidson MH, Testolin LM, Maki KC, von Duvillard S, Drennan KB. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in post-menopausal women. Arch Intern Med. 1997;157:1186–92.

9. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75–8.

10. Stampfer MJ, Colditz GA, Willitt WC, Manson JR, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from Nurses' Health Study. New Engl J Med. 1991;325:756–62.

11. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JR. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol. 1991;164:489–94.

12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–37.

13. Barrett-Conner E. Hormone replacement therapy. BMJ. 1998;317:457–61.

14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–13.

15. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among post-menopausal hormone users. Results from a national cohort. Arch Intern Med. 1993;153:73–9.

16. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769–75.

17. Prestwood KM, Kenny AM. Osteoporosis: pathogenesis, diagnosis, and treatment in older adults. Clin Geriatr Med. 1998;14:577–99.

18. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1981;1:459–61.

19. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, et al. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med. 1991;325:1189–95.

20. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol. 1990;76:290–5.

21. Kiehl DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med. 1987;317:1169–74.

22. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.

23. Lieberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437–43.

24. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–41.

25. Storm T, Thamsborg G, Steiniche T, Genant KH, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990;322:1265–71.

26. Overgaard K, Lindsay R, Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther. 1995;17:680–5.

27. Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, et al. A double-blind, placebo-controlled dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med. 1995;98:452–8.

28. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–7.

29. Yaffe K, Sawaya G, Liegerburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688–95.

30. Cauley JA, Seeley DG, Browner WS, Ensrud K, Kuller LH, Lipschutz RC, et al. Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. Arch Intern Med. 1997;157:2181–7.

31. Gambrell RD Jr. Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol. 1997;177:1196–204.

32. Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and post-menopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol. 1997;176:377–80.

33. Raisz LG, Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in menopausal women. J Clin Endocrinol Metab. 1996;81:37–43.

34. Watts NB, Notelovitz M, Timmons MC, Addison WA, Witta B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol. 1995;85:529–37[Published erratum in Obstet Gynecol 1995;85(5 pt 1):668]

35. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156:1332–4.

36. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–37.

37. Reuben DB, Yoshikawa TT, Besdine RW, eds. Geriatrics review syllabus: a core curriculum in geriatric medicine. 3d ed. New York: American Geriatrics Society; Dubuque, Iowa: Kendall/Hunt, 1996.

38. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589–93.

39. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350:1047–59.

40. Tyler VE. The honest herbal: a sensible guide to the use of herbs. 3d ed. New York: Pharmaceutical Products Press, 1993.

41. Weed SS. Menopausal years: the wise woman way. New York: Ash Tree, 1992.

42. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol. 1996;87(5 pt 2):897–904.

43. Physicians desk reference for herbal medicines. 1st ed. Montvale, N.J.: Medical Economics, 1999:647, 746, 875, 1222.

44. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, et al. Hypovitaminosis D in medical inpatients. N Eng J Med. 1998;338:778–83.

45. Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ, Ross EM, et al. Patient-specific decisions about hormone replacement therapy in post-menopausal women. JAMA. 1997;277:1140–7.

46. Guidelines for counseling postmenopausal women about preventive hormone therapy. American College of Physicians. Ann Intern Med. 1992;117:1038–41.



Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article